First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) Stock Price Up 0.6% – Here’s Why

Shares of First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) shot up 0.6% during trading on Monday . The company traded as high as $40.89 and last traded at $40.72. 9,304 shares changed hands during trading, a decline of 96% from the average session volume of 222,559 shares. The stock had previously closed at $40.47.

First Trust Nasdaq Pharmaceuticals ETF Price Performance

The stock has a market cap of $1.05 billion, a P/E ratio of 14.51 and a beta of 0.46. The company has a fifty day moving average of $40.07 and a 200 day moving average of $36.67.

First Trust Nasdaq Pharmaceuticals ETF Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Thursday, June 25th were issued a dividend of $0.092 per share. This represents a $0.37 annualized dividend and a yield of 0.9%. The ex-dividend date was Thursday, June 25th. This is a boost from First Trust Nasdaq Pharmaceuticals ETF’s previous quarterly dividend of $0.06.

Institutional Trading of First Trust Nasdaq Pharmaceuticals ETF

Institutional investors have recently made changes to their positions in the stock. Marshall Investment Management LLC purchased a new stake in shares of First Trust Nasdaq Pharmaceuticals ETF during the 4th quarter worth about $1,377,000. Nilsine Partners LLC lifted its stake in shares of First Trust Nasdaq Pharmaceuticals ETF by 3.5% in the second quarter. Nilsine Partners LLC now owns 28,057 shares of the company’s stock worth $1,071,000 after buying an additional 937 shares during the last quarter. Vivaldi Capital Management LP lifted its position in First Trust Nasdaq Pharmaceuticals ETF by 16.0% during the 1st quarter. Vivaldi Capital Management LP now owns 12,590 shares of the company’s stock worth $433,000 after acquiring an additional 1,741 shares during the last quarter. Flputnam Investment Management Co. bought a new stake in First Trust Nasdaq Pharmaceuticals ETF during the 4th quarter valued at approximately $230,000. Finally, Compass Financial Management LLC bought a new position in First Trust Nasdaq Pharmaceuticals ETF in the 2nd quarter worth approximately $29,000.

About First Trust Nasdaq Pharmaceuticals ETF

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.